LINEAGE CELL THERAPEUTICS INC LCTX 深 滬
等待開盤 08-15 09:30:00 美东时间
1.02
-0.010
-0.97%
華盛通- 最 高1.0488
- 今 開1.01
- 成交量 83.26万股
- 最 低 1.00
- 昨 收 1.03
- 總市值 2.33亿
- 52周最高 1.21
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.3651
- 委 比 66.41%
- 總股本 2.28亿
- 歷史最高 3.132
- 量 比 0.83
- 振 幅 4.74%
- 歷史最低 0.3651
- 每 手 1
- 風險率 0.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Update: Lineage Cell Therapeutics Q2 Adj. EPS $(0.07) Misses $(0.03) Estimate, Sales $2.765M Beat $1.472M Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 159.26 percent. This is a 133.33 percent decrease over losses of $(0.03) per
08-13 04:04
Here are the major earnings after the close Tuesday
Major earnings expected after the bell on Tuesday include: CoreWeave (CRWV) Inovio Pharmaceuticals (INO) Luminar Technologies (LAZR) Lumentum Holdings (LITE) Gladstone Investment Corporation (GAIN) Ot...
08-12 22:00
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
A Peek at Lineage Cell Therapeutics's Future Earnings
Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earni...
08-12 04:02
Lineage Cell Therapeutics Announced The First Chronic Spinal Cord Injury Patient Has Been Treated In The Company's DOSED Clinical Study, Evaluating A New Parenchymal Spinal Delivery System
The DOSED study is designed to evaluate the safety and utility of a new parenchymal spinal delivery system, a novel delivery device developed to deliver OPC1 directly to the site of injury in patients with spinal cord
08-04 20:10
美股大行评级 | 买入！Darden Restaurants获多家大行上调目标价；瑞银维持特斯拉"卖出"评级，目标价升至215美元
买入！Darden Restaurants获多家大行上调目标价；瑞银维持特斯拉"卖出"评级，目标价升至215美元>>
06-24 10:07
Lineage Therap Reports Promising OpRegen Study Results
An announcement from Lineage Therap ( ($LCTX) ) is now available. Lineage Cell ...
06-24 02:55
Lineage's OpRegen Shows +9 Letter BCVA Gains At 3 Years With Extensive Cell Coverage In Phase 1/2a Trial For Geographic Atrophy
Mean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to the Geographic Atrophy (GA) lesion siteEvidence of retinal structural improvement persisted out to 3 yearsAnatomical and
06-23 19:09
Lineage Cell Therapeutics Q1 EPS $(0.02) Beats $(0.03) Estimate, Sales $1.50M Miss $1.87M Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 50 percent increase over losses of $(0.04) per share
05-14 05:22
Earnings Scheduled For May 13, 2025
Companies Reporting Before The Bell • Endeavour Silver (NYSE:EXK) is estimated ...
05-13 16:32
